Quest Diagnostics reported first-quarter 2026 revenue of $2.895 billion, up 9.2% from $2.652 billion a year earlier, with organic revenue growth of 9.0%.
Diagnostic information services revenue rose 9.4% to $2.832 billion from $2.589 billion.
Requisition volume increased 10.9%, while revenue per requisition fell 1.3%.
Operating income climbed 15.5% to $399 million from $346 million, and operating margin widened to 13.8% from 13.0%.
Net income attributable to Quest Diagnostics increased 14.4% to $252 million from $220 million.
Diluted earnings per share rose 15.5% to $2.24 from $1.94.
On the adjusted basis, operating income rose 10.0% to $447 million from $406 million, net income attributable to Quest Diagnostics increased 12.1% to $281 million from $251 million, and diluted EPS rose 13.1% to $2.50 from $2.21.
Cash provided by operations fell 11.6% to $278 million from $314 million, while capital expenditures edged down 1.8% to $114 million from $117 million.
For 2026, Quest raised its revenue outlook to $11.78 billion to $11.90 billion from $11.70 billion to $11.82 billion. That implies growth of 6.8% to 7.8%, up from the prior range of 6.0% to 7.1%.
The company also lifted its full-year reported diluted EPS outlook to $9.58 to $9.78 from $9.45 to $9.65, and its adjusted diluted EPS outlook to $10.63 to $10.83 from $10.50 to $10.70.
Full-year cash from operations remains expected at approximately $1.75 billion, and capital expenditures remain targeted at approximately $550 million. As a result of these announcements, the company's shares have moved 0.86% on the market, and are now trading at a price of $198.15. For the full picture, make sure to review QUEST DI's 8-K report.
